GSK, Medicago launch late-stage trial of plant-derived COVID-19 vaccine
GlaxoSmithKline (GSK) and Canadian biopharma company Medicago have launched a Phase III trial of their adjuvanted plant-derived COVID-19 vaccine candidate.
The vaccine candidate uses Coronavirus-Like-Particle (CoVLP) technology, composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) administered alongside GSK’s pandemic adjuvant.
Medicago said it has received approval from Canadian and US regulatory authorities to begin enrolment of healthy adults into the Phase III trial based on ‘positive interim Phase II results’.
The adjuvanted plant-derived vaccine candidate received a fast track designation from the US Food and Drug Administration (FDA) in February 2021.
The Phase III portion of the study will evaluate the efficacy and safety of the adjuvanted CoVLP formulation and will enrol up to 30,000 participants.
Read more: http://www.pharmatimes.com/news/gsk,_medicago_launch_late-stage_trial_of_plant-derived_covid-19_vaccine_1365371
The vaccine candidate uses Coronavirus-Like-Particle (CoVLP) technology, composed of recombinant spike (S) glycoprotein expressed as virus-like-particles (VLPs) administered alongside GSK’s pandemic adjuvant.
Medicago said it has received approval from Canadian and US regulatory authorities to begin enrolment of healthy adults into the Phase III trial based on ‘positive interim Phase II results’.
The adjuvanted plant-derived vaccine candidate received a fast track designation from the US Food and Drug Administration (FDA) in February 2021.
The Phase III portion of the study will evaluate the efficacy and safety of the adjuvanted CoVLP formulation and will enrol up to 30,000 participants.
Read more: http://www.pharmatimes.com/news/gsk,_medicago_launch_late-stage_trial_of_plant-derived_covid-19_vaccine_1365371
